Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Loxo Oncology CS (LOXO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195

Research Desk Line-up: Acceleron Pharma Post Earnings Coverage

LOXO : 75.07 (+0.21%)
XLRN : 38.71 (+4.71%)
Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer

Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.

RARE : 48.11 (-0.23%)
ACHN : 3.43 (-3.65%)
VRTX : 147.41 (-0.36%)
DVAX : 18.25 (-1.08%)
LOXO : 75.07 (+0.21%)
AMGN : 170.00 (-0.45%)
ZYME : 7.60 (-7.77%)
Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195

- Up to $1.55B in Upfront, Regulatory, and Commercial Milestones -

LOXO : 75.07 (+0.21%)
Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer

Bayer announced today that the company has entered into an exclusive global collaboration with Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, Connecticut (NASDAQ: LOXO) for the development...

LOXO : 75.07 (+0.21%)
Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer

WHIPPANY, N.J. , Nov. 14, 2017 /PRNewswire/ -- Bayer announced today that the company has entered into an exclusive global collaboration with Loxo Oncology, Inc., a biopharmaceutical company based...

ADS : 224.35 (-0.43%)
LOXO : 75.07 (+0.21%)
Loxo Oncology to Present at Upcoming Investor Conferences

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company will...

LOXO : 75.07 (+0.21%)
Loxo Oncology Announces Third Quarter 2017 Financial Results

- Larotrectinib New Drug Application (NDA) Submission to U.S. FDA on Track for Year End 2017 / Early 2018 -

LOXO : 75.07 (+0.21%)
Loxo Oncology Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Loxo Oncology Inc (NASDAQ: LOXO) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 8:00 AM Eastern Time....

LOXO : 75.07 (+0.21%)
Loxo Oncology to Announce Third Quarter 2017 Financial Results and Host Conference Call

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for...

LOXO : 75.07 (+0.21%)
Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset

- 75% Overall Response Rate by Independent Review; 80% Overall Response Rate by Investigator Assessment -

LOXO : 75.07 (+0.21%)
Today's Research Reports on Stocks to Watch: Zynerba Pharmaceuticals and Loxo Oncology

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / Zynerba scored a big win yesterday after announcing positive results from its trial of ZYN002, a cannabidiol gel that is aimed to reduce symptoms of fragile...

LOXO : 75.07 (+0.21%)
ZYNE : 13.88 (+5.47%)
Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced details of the LOXO-292...

LOXO : 75.07 (+0.21%)
Loxo Oncology Announces Initial LOXO-292 Clinical Data to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that its investigators will...

LOXO : 75.07 (+0.21%)
Stocks Under Scanner in the Biotech Space -- GlycoMimetics, Genocea Biosciences, Inotek Pharma, and Loxo Oncology

If you want a Stock Review on GLYC, GNCA, ITEK, or LOXO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, September 01, 2017, the NASDAQ...

ITEK : 2.47 (-0.40%)
GNCA : 1.15 (-1.71%)
LOXO : 75.07 (+0.21%)
GLYC : 12.27 (+0.74%)
Loxo Oncology to Present at Upcoming Investor Conferences

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company will...

LOXO : 75.07 (+0.21%)
Loxo Oncology Announces Second Quarter 2017 Financial Results

- Larotrectinib NDA Submission on Track for Year End 2017 / Early 2018 -

LOXO : 75.07 (+0.21%)
Featured Company News - Loxo Oncology Acquires Reversible BTK Inhibitor Program from UK Biotech Firm Redx Pharma

Research Desk Line-up: Gilead Sciences Post Earnings Coverage

LOXO : 75.07 (+0.21%)
GILD : 72.44 (+0.04%)
Loxo Oncology In Shares Up 53.3% Since SmarTrend's Buy Recommendation (LOXO)

SmarTrend identified an Uptrend for Loxo Oncology In (NASDAQ:LOXO) on May 23rd, 2017 at $48.71. In approximately 2 months, Loxo Oncology In has returned 53.31% as of today's recent price of $74.67.

LOXO : 75.07 (+0.21%)
Shares of LOXO Up 57.3% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Loxo Oncology In (NASDAQ:LOXO) on May 23rd, 2017 at $48.71. In approximately 1 month, Loxo Oncology In has returned 57.33% as of today's recent price of $76.63.

LOXO : 75.07 (+0.21%)
Look for Shares of Loxo Oncology In to Potentially Pullback after Yesterday's 3.72% Rise

Loxo Oncology In (NASDAQ:LOXO) traded in a range yesterday that spanned from a low of $76.00 to a high of $80.35. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high...

LOXO : 75.07 (+0.21%)

Van Meerten Stock Picks

My 5 Favorite Small Caps
This morning I wanted to find the 5 Small Cap Stocks that had the best returns over the past year but still appeared to have some more room to climb.
SEDG -0.20 , GDOT +0.11 , CTRL -1.36 , ESIO -0.65 , QNST +0.23
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.06% ) this morning are down 0.06% on concern Special Counsel Mueller's criminal investigation between Trump campaign officials and Russia is deepening. Two people familiar with the matter... Read More

Chart of the Day

Chart of the Day

D R Horton (DHI) is the Barchart Chart of the Day.  The home builder has a Trend Spotter buy signal, a Weighted Alpha of 77.13+ and gained 68.46% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed Friday with most contracts 4 – 6 1/2 cents higher, as Dec came back to only lose a half cent on the week. Pre-weekend profit taking gets some of the credit. The CFTC report on Friday showed the spec funds holding a new recor...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart